_1777292798912_197359786.jpg&w=48&q=75){kind=small}
Eye drugs against cancer
New research has revealed that drugs originally designed to treat glaucoma can be repurposed to combat aggressive cancers such as breast cancer, melanoma, and acute myeloid leukemia. The researchers found that all these cancers rely on a molecule called ROCK to promote their spread and invasiveness. ROCK functions by tightening the internal structure of cancer cells, causing them to adopt a rounded shape and enabling them to move through tissues. The study confirmed that certain biological markers can predict how cancer cells will respond to ROCK inhibitors, including the presence of defects in the E-Cadherin gene in breast cancer, activity of the NFKB pathway in skin cancer, and genetic changes in leukemia. Results were demonstrated through laboratory experiments on tumor samples and tests on mice, with the expectation that these markers will help identify patients who would benefit most from these drugs. The study also pointed out that utilizing currently approved and safe medications could accelerate the development of effective treatments, with plans to move into clinical trials soon, aiming to enhance therapies for aggressive cancers. This could represent a breakthrough in the treatment of some of the most dangerous types of cancer.
Notice: This Is an AI-Generated Summary
Comments (0)